Pharmaceutical firm Eris Lifesciences has received markets regulator Securities and Exchange Board of India’s (SEBI) approval to raise funds through an initial public offering (IPO). The IPO comprises 28.87 million shares through an offer for sale by ChrysCap and promoters. The company’s shares are proposed to be listed on the BSE and NSE.
The company had filed draft prospectus with Sebi in February and the markets regulator has issued final observation on the IPO papers on April 28. Listing will provide a public market for the equity shares in India. The lead managers for the issue are Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).
Eris Lifesciences is engaged in manufacturing, marketing and selling of branded generics within the chronic and acute categories of the Indian Pharmaceutical Market.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1530.00 |
Dr. Reddys Lab | 5802.00 |
Cipla | 1399.35 |
Zydus Lifesciences | 1051.90 |
Lupin | 1653.75 |
View more.. |